Simulación del habitat físico en un tramo del río Lozoya, utilizando el sistema PHABSIM

[EN] This paper presents the habitat simulation of a 609-m stretch of the Lozoya river for obtaining the availability of Weighted Usable Area (WUA) for adult, juvenile and fry life stages of Barbus bocagei (endemic species of the Iberian Peninsula); as well as for determining the flow that maximizes the WUA. For habitat simulation, the Physical Habitat Simulation System (PHABSIM) was used, which is part of the Instream Flow Incremental Methodology (IFIM). Physical habitat simulation was made using PHABSIM hydrodynamic and habitat models, as well as habitat preference models for target species. As a result, Weighted Usable Area-Flow Curves (WUA-Q) were obtained, where WUA distribution can be observed as a function of the stream flows of the Lozoya River stretch, and it can be identified that a flow of 1.45m3/s maximizes the Weighted Usable Area for the adult and juvenile life stages of Barbus bocagei. As for the fry life stage, HPU grows with flow, but it can be identified that HPU grows the most in a range between 0.2 and 1.45m3/s. WUA-Q curves provide valuable information to the manager and to the different users of fluvial resources for determining instream flow regimes in order to meet fluvial ecosystem conservation needs.[ES] En el presente trabajo se efectúa la simulación del hábitat físico de un tramo de 609 m del río Lozoya, con la finalidad de estimar la disponibilidad de hábitat potencialmente utilizable (HPU) por la especie Barbus bocagei (endémica de la península Ibérica), en sus estadios de vida adulto, juvenil y alevín; así como estimar el caudal que maximiza dicho HPU. Para tal efecto, se utilizó el sistema PHABSIM (Physical Habitat Simulation System), el cual forma parte de la metodología IFIM (Instream Flow Incremental Methodology). En el PHABSIM se realiza la simulación del hábitat fluvial utilizando modelos de simulación de la hidrodinámica, del hábitat y modelos de las preferencias de hábitat de la(s) especie(s) objetivo, obteniendo como resultado la evolución del HPU en función del caudal del río, la cual se plasma gráficamente en las curvas caudal-hábitat potencialmente utilizable (Q-HPU); en las que se identificó, para el presente trabajo, que el caudal que maximiza el HPU para los estadios de vida adulto y juvenil de la especie Barbus bocagei es del orden de 1.45m3/s. En el caso del estadio alevín, la tendencia del HPU es a crecer con el caudal, pero se identifica que en el intervalo de caudales comprendido entre 0.2 y 1.45 m3/s se da el mayor crecimiento. Las curvas Q-HPU proporcionan información valiosa al gestor, y a los diferentes usuarios de los recursos fluviales, para determinar regímenes de caudales ecológicos destinados a la conservación del ecosistema correspondiente.García-Rodríguez, E.; Martínez-Austria, P.; García De Jalón De La Lastra, D.; Martinez-Capel, F. (2008). Simulación del habitat físico en un tramo del río Lozoya, utilizando el sistema PHABSIM. Ingeniería hidráulica en México. XXIII(4):41-52. http://hdl.handle.net/10251/33326S4152XXIII

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic

This study aimed to describe the change in surgical practice and the impact of SARS-CoV-2 on mortality after surgical resection of colorectal cancer during the initial phases of the SARS-CoV-2 pandemic

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death. CONCLUSION: The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Temperature and Heat-Related Mortality Trends in the Sonoran and Mojave Desert Region

Extreme temperatures and heat wave trends in five cities within the Sonoran Desert region (e.g., Tucson and Phoenix, Arizona, in the United States and Ciudad Obregon and San Luis Rio Colorado, Sonoraand Mexicali, Baja California, in Mexico) and one city within the Mojave Desert region (e.g., Las Vegas, Nevada) were assessed using field data collected from 1950 to 2014. Instead of being selected by watershed, the cities were selected because they are part of the same arid climatic region. The data were analyzed for maximum temperature increases and the trends were confirmed statistically using Spearman's nonparametric test. Temperature trends were correlated with the mortality information related with extreme heat events in the region. The results showed a clear trend of increasing maximum temperatures during the months of June, July, and August for five of the six cities and statically confirmed using Spearman's rho values. Las Vegas was the only city where the temperature increase was not confirmed using Spearman's test, probably because it is geographically located outside of the Sonoran Desert or because of its proximity to the Hoover Dam. The relationship between mortality and temperature was analyzed for the cities of Mexicali, Mexico and Phoenix. Arizona

The Human Right to Water in Mexico: Challenges and Opportunities

This article analyses Mexico's 2012 constitutional guarantee of the human right to water and the new General Water Law that is required to implement it. Mexico has struggled to find consensus regarding a new law, but none has as yet been adopted. We examine three key questions regarding the 2012-2019 period: How is the human right to water defined in the Mexican context? What is the legal and institutional framework for implementing it? What are the opportunities and challenges involved in institutionalising it in light of the proposed water legislation? This research is based on a literature review, participation and observation at public forums, and in-depth interviews with key actors. Two principal legal proposals emerged in 2015, contrasting a technocratic approach with a socially inclusive one; neither was adopted but both remain relevant to the current discourse. The 2018 election re-energised social mobilisation around the right to water, and the government launched a new process for developing legal proposals. Using legal geography and political ecology as theoretical framings, we find that the new law creates opportunities for transforming access to water for marginalised communities, yet faces social, political and structural obstacles. Despite the challenges, the constitutional guarantee of the right to water is a positive foundation for democratising water governance in Mexico.Open access articleThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

Comparison of clinical outcomes between femtosecond laser-assisted versus conventional phacoemulsification

Abstract Background To compare femtosecond laser-assisted versus conventional phacoemulsification in terms of visual and refractive outcomes, cumulative dissipated energy, anterior chamber inflammation and endothelial cell loss. Methods In this retrospective cohort study, records of eyes that underwent femtosecond laser-assisted cataract surgery (FLACS) or conventional phacoemulsification (CP) were reviewed. The Victus femtosecond laser (Bausch and Lomb, Germany) was used to carry out corneal incisions, anterior capsulotomy, and lens fragmentation in FLACS procedures. Manifest refraction spherical equivalence (MRSE), uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), cumulative dissipated energy (CDE), postoperative cells and flare and endothelial cell count data were collected. Subgroup analysis of the visual acuity tests was performed based on the type of intraocular lens implanted (monofocal, monofocal toric, multifocal, multifocal toric, accommodating). Results A total of 735 eyes were included in the study (296 eyes for the FLACS group and 439 eyes for the CP group). At one year follow-up, 120 eyes comprised the FLACS group and 265 eyes for the CP group. MRSE in the FLACS group was − 0.16 ± 0.58 D and − 0.20 ± 0.52 D in the CP group (P = 0.50). UDVA in the FLACS group was 20/25 (mean logMAR 0.12 ± 0.13) and 20/25 (mean logMAR 0.11 ± 0.13) in the CP group (P = 0.48). CDVA was 20/20 (mean logMAR 0.03 ± 0.07) in the FLACS group and 20/20 (mean logMAR 0.02 ± 0.06) in the CP group (P = 0.15). No statistically significant trend was seen for FLACS versus CP by intraocular type for visual acuity. CDE for the different cataract grades ranged from 6.97 ± 5.74 to 29.02 ± 16.07 in the FLACS group and 7.59 ± 6.42 to 35.69 ± 18.30 in the CP group. The FLACS group was significantly lower for post-operative central corneal edema (P = 0.05), cells and flare (P = 0.01), and endothelial cell loss (P = 0.04). Conclusions Femtosecond laser-assisted cataract surgery and conventional phacoemulsification had similar refractive and visual outcomes. Phacoemulsification energy, anterior chamber inflammation and corneal endothelial cell loss were less in the femtosecond laser group